Literature Scan

Literature Scan

New and noteworthy research from the medial literature landscape

No Added Benefit When Hydroxyurea Is Combined With Aspirin in Middle-Aged Patients With Essential...

Cytoreductive treatment with hydroxyurea has been shown to reduce the risk of thrombosis in patients with essential thrombocythemia (ET) and high-risk features, which include...

Researchers Identify Genetic Prognostic Predictors in Myeloproliferative Neoplasms

A team of European and American researchers have identified and characterized associations between specific genetic mutations and prognosis in patients with myeloproliferative neoplasms (MPNs),...

BCMA-Targeting CAR T-Cell Therapy Shows High Response Rate in Pretreated Myeloma

Multiple myeloma (MM) is a potential target for chimeric antigen receptor (CAR) T-cell therapies, according to final results from a first-in-human trial of B-cell...

A New Source of “Superwarfarin” Poisoning: Increased Bleeding Risk After Synthetic Cannabinoid Use

In the New England Journal of Medicine (NEJM), authors reported a case series of patients with synthetic cannabinoid–associated coagulopathy, identifying contamination with brodifacoum, or...

Higher Childhood Leukemia Risk in Offspring Raises Questions About Hormonal Contraceptive Safety

Children born to women who were using hormonal contraception within three months of pregnancy and during pregnancy have a higher risk of developing myeloid...

Post-Transplant Gene Mutations Predict Risk for MDS Progression

Sequencing bone marrow samples early after patients with myelodysplastic syndromes (MDS) have undergone allogeneic hematopoietic cell transplantation (AHCT) could help identify patients who are...

Rivaroxaban Fails to Prevent VTE and VTE-Related Mortality After Hospital Discharge

Patients hospitalized for an acute medical illness are at an increased risk for developing venous thromboembolism (VTE) in the six weeks after discharge, but...

Rituximab Plus Lenalidomide Noninferior to Chemotherapy in Treatment-Naïve Follicular Lymphoma

Treatment with the chemotherapy-free combination of rituximab and the immunomodulatory agent lenalidomide (R2) was noninferior to the combination of rituximab and chemotherapy (R-chemo) in...

Phase I Trial Shows Activity of Single-Agent Ivosidenib in IDH1-Mutated AML

Ivosidenib was safe and associated with remissions, transfusion independence, and molecular remissions in patients with relapsed or refractory IDH1-mutated acute myeloid leukemia (AML), according...

Oral L-Glutamine Powder Lowers Frequency of Sickle Cell–Related Pain Episodes

Oral L-glutamine powder, with or without hydroxyurea, reduced the number of pain events experienced by children and adults with sickle cell disease (SCD), compared...
Advertisement

Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.